Who Exports Bisacodyl from India — 240 Suppliers Behind a $8.6M Market
India's bisacodyl export market is supplied by 240 active exporters who collectively shipped $8.6M across 1,294 shipments. DR.REDDY'S LABORATORIES LTD leads with a 22.9% market share, followed by IND SWIFT LIMITED and BLISS GVS PHARMA LIMITED. The top 5 suppliers together control 50.0% of total export value, reflecting a moderately competitive market structure.
Top Bisacodyl Exporters from India — Ranked by Export Value
DR.REDDY'S LABORATORIES LTD is the leading bisacodyl exporter from India, holding a 22.9% share of the $8.6M market across 1,294 shipments from 240 exporters. The top 5 suppliers — DR.REDDY'S LABORATORIES LTD, IND SWIFT LIMITED, BLISS GVS PHARMA LIMITED, DR REDDYS LABORATORIES LIMITED, MEDREICH LIMITED — collectively control 50.0% of total export value, indicating a competitive market. Individual shares are: DR.REDDY'S LABORATORIES LTD (22.9%), IND SWIFT LIMITED (8.8%), BLISS GVS PHARMA LIMITED (8.3%), DR REDDYS LABORATORIES LIMITED (5.3%), MEDREICH LIMITED (4.6%).
Top Bisacodyl Exporters from India
Ranked by export value · 240 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD BISACODYL TABLETS BP 5.0MGBISACODYL BP 5.0MGEACH ENTERIC-COATED TABLET CONTAINS: BISACODYL BP 5.0MG | $2.0M | 1 | 22.9% |
| 2 | IND SWIFT LIMITED BISACODYL TABLETS BP 5.0MGBISACODYL BP 5.0MGEACH ENTERIC-COATED TABLET CONTAINS: BISACODYL BP 5.0MG | $760.7K | 1 | 8.8% |
| 3 | BLISS GVS PHARMA LIMITED | $712.9K | 3 | 8.3% |
| 4 | DR REDDYS LABORATORIES LIMITED BISACODYL TABLETS BP 5.0MGBISACODYL BP 5.0MGEACH ENTERIC-COATED TABLET CONTAINS: BISACODYL BP 5.0MG | $458.7K | 1 | 5.3% |
| 5 | MEDREICH LIMITED BISACODYL 5MG TABLETSBISACODYL 5MG TABLETS 3X10'SBISACODYL GASTRO RESISTANT TABLETS 5MG,30000S234.972 | $399.9K | 5 | 4.6% |
| 6 | DR.REDDY'S LABORATORIES LIMITED BISACODYL TABLETS BP 5.0MGBISACODYL BP 5.0MGEACH ENTERIC-COATED TABLET CONTAINS: BISACODYL BP 5.0MG | $291.9K | 1 | 3.4% |
| 7 | DR REDDY S LABORATORIES LIMITED BISACODYL TABLETS BP 5.0MGBISACODYL BP 5.0MGEACH ENTERIC-COATED TABLET CONTAINS: BISACODYL BP 5.0MG | $282.8K | 1 | 3.3% |
| 8 | ZYDUS LIFESCIENCES LIMITED ZYCOLAX FORTE 10MG TABS (BISACODYL DELAYZYCOLAX 10 SUPPOS 10MG 5S (BISACODYL SUP | $258.5K | 4 | 3.0% |
| 9 | ARAVIS PHARMACEUTICALS FORMULATION TABLETS BASALAX-5 TAB BISACODYL BP 5MGPHARMACEUTICAL DRUGS & MEDICINES "CAMUOLAX" | $230.9K | 1 | 2.7% |
| 10 | ADCOCK INGRAM LIMITED FRESHEN BISACODYL 5MG TBLETS 121824X1BROOKLAX 5MG TABLETS 10S PACKFRESHEN 120600X1 | $214.6K | 1 | 2.5% |
| 11 | IND-SWIFT LIMITED BISACODYL TABLETS BP 5.0MGBISACODYL BP 5.0MGEACH ENTERIC-COATED TABLET CONTAINS: BISACODYL BP 5.0MG | $203.4K | 1 | 2.4% |
| 12 | AUROBINDO PHARMA LTD BISACODYL DELAYED-RELEASE TABS5MG30'SBISACODYL DELAYED-RELEASE TABLETS 5 MG 30'SBISACODYL DELAYED-RELEASE TABLETS5MG30'S | $202.5K | 2 | 2.3% |
| 13 | HIGLANCE LABORATORIES PRIVATE LIMITED BISCAD BISACODYL DELAYED RELEASE TABLETBIKONOR B.NO.;230BISCAD BISACODYL DELAYED RELEASE TABLET5MG | $143.9K | 1 | 1.7% |
| 14 | IND-SWIFT LTD BISACODYL TABLETS BP 5.0MGBISACODYL BP 5.0MGEACH ENTERIC-COATED TABLET CONTAINS: BISACODYL BP 5.0MG | $112.5K | 1 | 1.3% |
| 15 | BDH INDUSTRIES LIMITED ZYCOLAX FORTE 10MG TABS (BISACODYL DELAYZYCOLAX 10 SUPPOS 10MG 5S (BISACODYL SUP | $110.0K | 3 | 1.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Bisacodyl exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd | Not Listed | Yes (multiple facili | Unknown | Not verified | WHO-GMP certified for multiple facilities as per CDSCO. |
| Aurobindo Pharma Limited | Warning Letter (January 2 | Yes (Unit IX certifi | Unknown | Not verified | Received FDA Warning Letter in January 2022; WHO-GMP certified for Unit IX. |
| Zydus Lifesciences Limited | Warning Letter (August 20 | Unknown | Unknown | Not verified | Received FDA Warning Letter in August 2024; closeout letter issued December 2025 |
| Intas Pharmaceuticals Limited | Warning Letter (November | Unknown | Unknown | Not verified | Received FDA Warning Letter in November 2023 for Ahmedabad facility. |
| Glenmark Pharmaceuticals Limited | Warning Letter (July 2025 | Unknown | Unknown | Not verified | Received FDA Warning Letter in July 2025 for Pithampur facility. |
| Unexo Lifesciences Private Limited | Warning Letter (November | Unknown | Unknown | Not verified | Received FDA Warning Letter in November 2024 for New Delhi facility. |
| GPT Pharmaceuticals Private Ltd | Warning Letter (December | Unknown | Unknown | Not verified | Received FDA Warning Letter in December 2019 for Hyderabad facility. |
| Aurolife Pharma, LLC | Warning Letter (October 2 | Unknown | Unknown | Not verified | Received FDA Warning Letter in October 2020 for New Jersey facility. |
TransData Nexus reviewed the regulatory standing of 8 leading Bisacodyl exporters from India. 0 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 0 are EU GMP compliant. 7 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Bisacodyl sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city's pharmaceutical ecosystem is bolstered by a robust infrastructure and a skilled workforce, making it a pivotal hub for API manufacturing. Companies like Dr. Reddy's Laboratories, headquartered in Hyderabad, have significantly contributed to the city's prominence in the pharmaceutical sector. Dr. Reddy's Laboratories is a leading exporter of Bisacodyl, accounting for 22.9% of total exports, valued at $2.0 million.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara belt in Gujarat is a major center for pharmaceutical formulations. This region hosts numerous manufacturing units specializing in the production of finished dosage forms, including tablets and capsules. Companies such as Cadila Pharmaceuticals, based in Ahmedabad, play a significant role in this cluster. Cadila Pharmaceuticals is involved in the manufacturing of various pharmaceutical products, contributing to the region's reputation as a formulations hub.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway for India's pharmaceutical products. Mumbai, being a major port city, facilitates the global distribution of pharmaceuticals. Companies like Cipla, headquartered in Mumbai, have a significant presence in this region. Cipla operates multiple manufacturing units and has a strong export orientation, contributing to the region's status as an export hub.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, largely due to favorable tax incentives. Baddi is home to numerous pharmaceutical companies, including Dr. Reddy's Laboratories, which has manufacturing facilities in the area. The region's strategic location and policy benefits have attracted significant investment, making it a key player in the pharmaceutical industry.
5Sourcing Recommendations
- Engage with Established Exporters: Prioritize sourcing from top exporters like Dr. Reddy's Laboratories, which holds a 22.9% share of Bisacodyl exports, ensuring reliability and quality.
- Leverage Regional Specializations: Utilize the strengths of specific clusters, such as Hyderabad for APIs and Ahmedabad-Vadodara for formulations, to optimize the supply chain.
- Consider Export Hubs: Collaborate with manufacturers in the Mumbai-Thane-Raigad region to facilitate smoother international logistics and distribution.
- Explore Tax Incentive Zones: Assess the benefits of sourcing from the Baddi-Nalagarh region, where tax incentives may offer cost advantages.
By strategically engaging with these pharmaceutical clusters, companies can enhance their sourcing strategies for Bisacodyl, ensuring quality, cost-effectiveness, and efficient distribution.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Bisacodyl exporters from India
Dr. Reddy's Laboratories Ltd. — Acquisition of India trademarks for two HRT drugs
On February 18, 2026, Dr. Reddy's Laboratories entered into a definitive agreement with Mercury Pharma Group Limited to acquire the India trademarks for specialty brands Progynova® and Cyclo-Progynova®, along with related assets, for $32.15 million. This acquisition strengthens Dr. Reddy's gynecology portfolio and marks its entry into the Hormone Replacement Therapy segment in India. - IMPACT: This acquisition is not expected to directly impact Bisacodyl exports, as it focuses on expanding the company's gynecology portfolio within the Indian market.
Impact: This acquisition is not expected to directly impact Bisacodyl exports, as it focuses on expanding the company's gynecology portfolio within the Indian market.
Common Questions — Bisacodyl Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which bisacodyl supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, DR.REDDY'S LABORATORIES LTD leads with 78 recorded shipments worth $2.0M. IND SWIFT LIMITED (26 shipments) and BLISS GVS PHARMA LIMITED (26 shipments) are also established high-volume exporters.
Q How many bisacodyl manufacturers are there in India?
India has 240 active bisacodyl exporters with a combined export market of $8.6M across 1,294 shipments to 108 countries. The top 5 suppliers hold 50.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for bisacodyl from India?
Average FOB unit price: $5.76 per unit, ranging from $0.00 to $1609.87. Average shipment value: $6.7K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 240 verified Indian exporters of Bisacodyl ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,294 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 108 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,294 Verified Shipments
240 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists